Therapeutic targeting of HMGB1 during experimental sepsis modulates the inflammatory cytokine profile to one associated with improved clinical outcomes

Sepsis remains a significant health burden and a major clinical need exists for therapeutics to dampen the excessive and uncontrolled immune activation. Nuclear protein high mobility group box protein 1 (HMGB1) is released following cell death and is a late mediator in sepsis pathogenesis. While app...

Descripción completa

Detalles Bibliográficos
Autores principales: Stevens, Natalie E., Chapman, Marianne J., Fraser, Cara K., Kuchel, Tim R., Hayball, John D., Diener, Kerrilyn R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5517568/
https://www.ncbi.nlm.nih.gov/pubmed/28724977
http://dx.doi.org/10.1038/s41598-017-06205-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5517568/
https://www.ncbi.nlm.nih.gov/pubmed/28724977
http://dx.doi.org/10.1038/s41598-017-06205-z

Ejemplares similares